Loading...
Actinogen Medical Limited
ATGGF•PNK
Healthcare
Biotechnology
$0.03
$0.00(0.00%)
Actinogen Medical Limited (ATGGF) Financial Performance & Income Statement Overview
Review Actinogen Medical Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
103.18%
↑ 103.18%
Operating Income Growth
19.11%
↑ 19.11%
Net Income Growth
-21.32%
↓ 21.32%
Operating Cash Flow Growth
-94.88%
↓ 94.88%
Operating Margin
-75.11%
↓ 75.11%
Gross Margin
97.76%
↑ 97.76%
Net Profit Margin
-137.64%
↓ 137.64%
ROE
-76.18%
↓ 76.18%
ROIC
-35.67%
↓ 35.67%
Actinogen Medical Limited (ATGGF) Income Statement & Financial Overview
Review Actinogen Medical Limited's (ATGGF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $9.02M | $909030.00 | $1.94M | $1.94M |
| Cost of Revenue | $0.00 | $211968.00 | $204553.00 | $0.00 |
| Gross Profit | $9.02M | $697062.00 | $1.74M | $1.94M |
| Gross Profit Ratio | $1.00 | $0.77 | $0.89 | $1.00 |
| R&D Expenses | $6.58M | $8.95M | $3.52M | $1.76M |
| SG&A Expenses | $3.84M | $3.40M | $3.67M | $1.83M |
| Operating Expenses | $10.42M | $12.35M | $7.18M | $3.71M |
| Total Costs & Expenses | $10.42M | $12.56M | $7.39M | $3.71M |
| Interest Income | $184247.00 | $106774.00 | $230742.00 | $112102.00 |
| Interest Expense | $13177.00 | $11115.00 | $6538.00 | $0.00 |
| Depreciation & Amortization | $163188.00 | $211968.00 | $204553.00 | $102276.00 |
| EBITDA | -$1.44M | -$12.24M | -$1.67M | -$1.67M |
| EBITDA Ratio | -$0.16 | -$13.59 | -$3.70 | -$0.86 |
| Operating Income | -$1.40M | -$12.56M | -$7.39M | -$1.75M |
| Operating Income Ratio | -$0.15 | -$13.82 | -$3.80 | -$0.90 |
| Other Income/Expenses (Net) | -$9.11M | $96464.00 | -$5.55M | $95409.00 |
| Income Before Tax | -$10.51M | -$12.47M | -$7.20M | -$1.66M |
| Income Before Tax Ratio | -$1.16 | -$13.71 | -$3.71 | -$0.85 |
| Income Tax Expense | -$9.02M | -$909030.00 | -$3.88M | $0.00 |
| Net Income | -$1.49M | -$11.56M | -$3.31M | -$1.66M |
| Net Income Ratio | -$0.16 | -$12.71 | -$1.71 | -$0.85 |
| EPS | -$0.001 | -$0.005 | -$0.002 | -$0.001 |
| Diluted EPS | -$0.001 | -$0.005 | -$0.002 | -$0.001 |
| Weighted Avg Shares Outstanding | $2.29B | $2.34B | $1.92B | $1.79B |
| Weighted Avg Shares Outstanding (Diluted) | $2.28B | $2.34B | $1.92B | $1.79B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan